Timothy Schmidt, MD (@TMSchmidtMD) header
Timothy Schmidt, MD (@TMSchmidtMD) profile picture

Assistant Professor @UWCarbone. Proud @WinshipAtEmory, @uiccom, @slusom, @XavierU alum. Clinical investigator focusing on myeloma and plasma cell disorders.

Madison, WI
Joined July 2018
Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)Photo by Timothy Schmidt, MD (@TMSchmidtMD)
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
3
54
1
112
7,193
Timothy Schmidt, MD retweeted
ASH has released new Clinical Practice Guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening bone marrow disorder. The guidelines present 12 evidence-based recommendations designed to help clinicians improve diagnosis. ow.ly/OMEV50Y4S71
22
5
51
11,509
Timothy Schmidt, MD retweeted
#Myeloma Paper of the Day: American Society of Hematology (ASH) 2026 guidelines on diagnosis of light chain/AL #amyloidosis emphasizing serum & urine immunofixation, serum free light chains, and surrogate biopsies (both bone marrow and fat pad): pubmed.ncbi.nlm.nih.gov/4159…. #mmsm
2
29
83
5,837
Timothy Schmidt, MD retweeted
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0: 📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades. 🧪 Neutrophils: Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded. Stricter G4: threshold drops from <500 to <100/mm³. 🩸 Platelets (Thrombocytopenia): Wider G3: Now covers 10k–50k (previously 25k–50k). Stricter G4: threshold drops from <25k to <10k/mm³. v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria. Overall, IMO these new thresholds align better with clinical practice. #ClinicalTrials #MedEd #OncTwitter #DrugSafety
3
104
4
193
24,669
Timothy Schmidt, MD retweeted
#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/3996…. #mmsm
1
23
3
68
8,859
Timothy Schmidt, MD retweeted
How do you approach patients with AL amyloidosis with high plasmacytosis in the bone marrow (ex. 35%) but no other evidence of myeloma?
27%DaraCyBorD->Dara
63%DaraCyBorD->ASCT if poss
5%DaraCyBorD->Dara+(V or R)
5%Other
111 votes • Final results
4
5
13
1,973
Timothy Schmidt, MD retweeted
Tune in to our new episode on quadruplets in newly diagnosed transplant-ineligible #Myeloma with @TMSchmidtMD! 🎙️ We break down the IMROZ & BENEFIT trials and how to apply them in our current practice. 🩺🔍 share.transistor.fm/s/6e20d2… Check out this short clip!
6
3
17
4,729
Timothy Schmidt, MD retweeted
Coming soon! Episode on newly diagnosed transplant-ineligible #MultipleMyeloma & in-depth analysis of 𝐈𝐌𝐑𝐎𝐙 and 𝐈𝐅𝐌-𝟐𝟎𝟐𝟎/𝐁𝐄𝐍𝐄𝐅𝐈𝐓 trials with @TMSchmidtMD! #EHA24 #ASCO24 #mmsm
4
11
1,515
Are you a myeloma clinician who orders FISH tests? If so, the CGC Plasma Cell Neoplasm Working Group is interested in your feedback! FISH reports can be confusing and we want to learn about your experiences to help optimize cytogenetic reports. Survey: surveymonkey.com/r/VKTFVTS
3
17
5
18
18,455
Timothy Schmidt, MD retweeted
One of my patients (who labels himself a #PriorAuthSurvivor) diagrammed the unnecessary complexity of trying to get his medication approved on time 👇 Rinse & repeat and this is a cyclic nightmare that has nothing to do with chemo but rather the bureaucracy of US healthcare
86
556
127
1,790
354,142
Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium onlinelibrary.wiley.com/doi/… @MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm
33
72
6,172
Timothy Schmidt, MD retweeted
Humoral immune reconstitution following daratumumab, carfilzomib, lenalidomide, & dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and MRD-response-adapted treatment cessation onlinelibrary.wiley.com/doi/… @End_myeloma @TMSchmidtMD #mmsm
5
9
859
Timothy Schmidt, MD retweeted
Chromosome 1 abnormalities are associated with worse outcomes in #MultipleMyeloma. In the retrospective analysis by Mohan et al, the combination of both gain(1q21) and del(1p13.3) had a greater impact on outcomes compared to either abnormality on its own. Read an accompanying editorial by Timothy Schmidt (@UWCarbone): acsjournals.onlinelibrary.wi…
Combined abnormalities of del (1p13.3) / 1q21gain or amp was significantly worse compared to del(1p13.3) alone and 1q21gain or 1q21 amp alone in #MultipleMyeloma (MM). This identifies a subset of MM patients with poor clinical outcomes. acsjournals.onlinelibrary.wi… @OncoAlert CC: @AjayNookaMD
2
5
1,062
Calling all physicians and researchers heading to @ASCO.  We’re hosting a reception on June 4.  Join us! @debgugel  #ASCO23
10
5
1,575